Can't buy the drug — must you fly abroad? Inside the special-import process that links cancer care to the world

When existing domestic medicines can no longer meet treatment needs, many patients and families spiral into the anxiety of 'there's a new drug abroad, but Taiwan can't buy it'. Taiwan's NHI is a global model, yet market size, R&D cost recovery and price review often delay new-drug licensure here by one to two years behind Europe and the US.

For cancer patients, those missing years are a daily race against time. When standard treatment hits a wall, besides seeking care overseas there is a legal path under the Pharmaceutical Affairs Act: special import.

This episode features Dr. Chiang Yi-hao of MacKay Memorial Hospital's hematology-oncology department and pharmacist Wang, business development manager at Chuan Meng Biotech, explaining what special import is.

1. What is special import? A green channel for urgent needs

Special import is not routine commercial sale. Under Article 48-2 of the Pharmaceutical Affairs Act, it is a remedial mechanism for urgent shortages, major public-health events, or the medical needs of specific patients.

Clinically, Dr. Chiang explains, when a patient has progressed to later lines of therapy and no reimbursed or licensed domestic option remains — but a drug proven effective abroad (FDA or EMA) exists — the physician can apply through the hospital to TFDA for special import.

It is a lawful path that keeps patients aligned with the latest international treatment guidelines, so that 'the medicine' is no longer an unreachable hope.

2. The expensive truth: why do special-import medicines cost more than expected?

Why does the same vial cost more via special import than abroad? Pharmacist Wang explains this is not profiteering but very high operating costs:

• First-class cold-chain transport: pharmaceutical shipping demands strict temperature control; at tiny volumes, the amortized freight can be many times the drug price.
• No bargaining power: special import is piecemeal procurement without bulk-purchase discounts.
• Support-program differences: patients abroad may enjoy manufacturer patient support programs; special-import products, lacking a domestic license, often cannot access those discounts.

Though costlier, the legal channel guarantees transparent provenance and stable quality, avoiding loss of efficacy from improper transport or storage.

3. Charting the treatment map with your physician — and making AI your dialogue tool

In the precision era, next-generation sequencing (NGS) pinpoints the target. Many patients now search international literature with AI tools and bring findings back to their physicians — a positive shift. Before pursuing special import, confirm three things with your attending physician:

• Completeness of the treatment plan: does the drug fit the current pathological stage? Is it the most reasonable next option?
• Off-label risk: some uses are off-label, requiring a more complex application and stronger literature support.
• A plan for the waiting period: from application to delivery takes one to three months. How will the physician adjust current treatment to keep the disease stable through the gap?

4. The last line of legal safety: drug injury relief

The greatest meaning of choosing lawful special import is protection. TFDA-led special imports for shortages or public-health needs are now covered by drug injury relief.

By contrast, generics brought back through illegal proxy purchase or informally from abroad are of unverifiable provenance — and if a serious adverse event occurs, Taiwan's relief system cannot help. Illegal importation may also carry criminal liability; don't lose big to save small.

Seeking a more dignified choice for life

Cancer treatment is a long campaign in which financial planning matters as much as medical decisions. Facing 'no drug' or 'too expensive':

• Consult the professional team: ask your physician or pharmacist to assess special import.
• Review insurance coverage: check whether your medical policies cover self-pay drug procurement, or use asset activation to fund care.
• Don't follow the crowd: patient groups are rich in information, but every genome differs — return to professional discussion.

Special import is arduous and costly, but it represents Taiwan's effort toward equal right to life. Through legal channels and professional teams, the anticancer road can be walked more steadily — and with dignity.